Charles River Labs Reports Q1 2026 Results: GAAP Loss, Non-GAAP EPS $2.06

Details

reported its first-quarter 2026 financial results, showing a GAAP loss per share of $(0.30) and non-GAAP earnings per share of $2.06. The company's revenue for the quarter was $995.8 million, a 1.2% increase from the prior year. The GAAP loss was primarily due to a loss on assets held for sale related to the divestiture of the CDMO and Cell Solutions businesses. The company also completed the divestiture of these businesses and repurchased $200 million of its common stock during the quarter. Charles River reaffirmed its 2026 guidance for organic revenue and non-GAAP earnings per share.

Items reported

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.